On March 22, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
The version 2.2021 update featured a change to second-line systemic therapy for locally advanced or metastatic disease (Stage IV; post-platinum). Atezolizumab was removed as an alternative preferred regimen based on the voluntary withdrawal of the FDA indication.—Janelle Bradley
